X4 Pharmaceuticals (XFOR) Common Equity (2017 - 2025)

X4 Pharmaceuticals has reported Common Equity for 9 years, with the latest figure at $186.3 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 741.08% year-over-year to $186.3 million; the trailing twelve-month figure through Dec 2025 stood at $186.3 million (up 741.08% YoY), and the FY2025 full-year result was $186.3 million, up 741.08% from the prior year.
• Common Equity for Q4 2025 stood at $186.3 million, up from $61.6 million in the prior quarter.
• The five-year high for Common Equity was $186.3 million in Q4 2025, with the low at $1.0 million in Q1 2024.
• Historically, Common Equity has averaged $61.6 million across 5 years, with a median of $61.7 million in 2022.
• Annual changes were most pronounced in 2024 — Common Equity sank 98.0% — and 2025, when it soared 2114.67%.
• X4 Pharmaceuticals' Common Equity stood at $64.4 million in 2021, then climbed by 14.96% to $74.1 million in 2022, then tumbled by 30.99% to $51.1 million in 2023, then plunged by 56.65% to $22.1 million in 2024, then jumped by 741.08% to $186.3 million in 2025.
• The last three Common Equity figures came in at $186.3 million (Q4 2025), $61.6 million (Q3 2025), and $4.0 million (Q2 2025), per Business Quant data.